Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.

From Diagnosis to Treatment - The Story of a Breast Cancer Patient, Part 4 of 4 Series on Molecular to Post Screening

PACE credits are no longer available for webinars more than 6 months old.

Overview

Part 4 of 4 series for a breast cancer patient involves the molecular, ePathology, and post screening section of the series.  The presentation will encompass an overview of molecular diagnosis and the implications to the patient.  The upcoming need and knowledge on how ePathology is being used in the anatomical pathology to help patient tumor panels or consultation will be reviewed.  Finally, the next step for patients after diagnosis with post screening and treatment will be discussed.

Learning Objectives:

1. To have a general understanding on molecular and diagnosis for breast cancer.

2. Overview on how ePathology and imaging helps with patient tumor panels and consultations.

3. Understanding of an overview of post screening and treatment of breast patients. 

Leica Biosystems webinars, training presentations and related materials provide general information regarding particular subjects and are not intended to be, and should not be construed as medical, regulatory or legal advice. The views and opinions expressed are the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents.

For the use of any product, the product information guides, inserts and operation manuals of the various products and devices should be consulted. Leica Biosystems and the editors disclaim any liability arising directly or indirectly from the use of devices, techniques or procedures described in these materials.

Copyright © 2016 by Leica Biosystems Richmond Inc. All rights reserved.LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.